focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Contract Win

16 Jan 2018 07:01

RNS Number : 9455B
Instem plc
16 January 2018
 

 

Instem plc

 

("Instem", the "Company" or the "Group")

 

SEND outsourced services contract win

 

Top five global nonclinical CRO outsources all SEND data set generation to Instem

 

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, is pleased to announce the award of a new two-year SEND ("Standard for the Exchange of Nonclinical Data") outsourced services contract by a top five global nonclinical contract research organisation ("CRO"), worth in excess of £1.7million over an initial two year period. Instem's expert SEND services team will use its proprietary SaaS-based submit™ technology platform throughout the engagement to create and review all of the CRO's SEND data packages.

 

The dedicated Instem team allocated to this CRO is expected to grow to around 15 people by the end of the first year of the contract as additional staff are recruited and trained. The team will transition from being predominantly UK/US based to predominantly India based over a 15-month period. Study volume is scheduled to ramp up through the contract period with revenue of at least £0.7m expected to be generated in 2018.

 

 

SEND submit™

Instem has been engaged in the development of SEND since 2004, recognising that the development of such a standard would be an important and transformational event for the industry. The US Food & Drug Administration ("FDA") mandated SEND for certain study types in December 2016 and a significant increase in industry SEND volume is now occurring following a second milestone in December 2017 for studies supporting the earlier stages of regulatory drug submission. The implementation of SEND is now a market imperative for the entire drug development industry.

 

Instem has assembled an experienced group of SEND experts, including several staff members that maintain leadership positions on the industry committees that both oversee the Standard and provide guidelines for its exploitation.

 

Instem's SEND services team produces and verifies SEND packages for clients across the globe with multiple requests currently being received from the USA, Japan, India and Europe. One of the unique strengths of Instem's SEND services team is its ability to blend its market-leading technology platform with an unrivalled professional services team, ensuring delivery of high quality output in competitive timescales. The Company pays close attention to both the regulatory and information security considerations of handling and processing precious customer data to ensure it minimises risk and time spent on quality control activities.

 

All study conversions are performed on a secure, hosted and validated SEND services platform, which is available and supported 24/7 utilising Instem's submit™ SEND software suite. This is the same submit™ software that is in production use at pharma and contract research organisations worldwide.

 

Phil Reason, CEO of Instem plc, commented: "Winning what we believe to be the largest outsourced SEND services contract ever awarded is clearly a huge endorsement of Instem and our SEND credentials.

 

"For several years, we have been presenting an anticipated substantial 2018 uplift in SEND study volume following the December 2017 FDA mandate, which is now materialising. With SEND data sets now on the critical path in the new drug development timeline, the industry will only work with partners that can quickly deliver to an exceptionally high quality, which puts Instem's people and technology in very high demand. This new CRO award, combined with commitments to other clients, means we are already contracted to deliver in 2018 over five times the number of SEND assignments completed in 2017."

 

 

For further information, please contact:

 

Instem plc

+44 (0) 1785 825 600

Phil Reason, CEO

Nigel Goldsmith, CFO

 

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

Richard Lindley

James White

Rachel Hayes

 

Walbrook Financial PR

+44 (0) 20 7933 8000

Paul Cornelius

instem@walbrookpr.com

Helen Cresswell

Sam Allen

 

About Instem

 

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.

 

Instem solutions are in use by customers worldwide and enable our clients to bring life enhancing products to market faster.

 

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

 

Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India.

 

To learn more about Instem solutions and its mission, please visit instem.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAFKPDDDBKBADD
Date   Source Headline
26th Jan 20073:07 pmRNSAcquisition of stake in INS
18th Dec 20063:09 pmRNSTotal Voting Rights
26th Sep 20067:00 amRNSInterim Results
30th Aug 20064:05 pmRNSNotice of Results
17th Jul 20063:21 pmRNSRe Contract
27th Jun 20063:53 pmRNSDirectors Dealings
6th Jun 20062:47 pmRNSDirector/PDMR Shareholding
5th Jun 20063:51 pmRNSHolding(s) in Company
2nd Jun 20064:49 pmRNSDirectors. dealings
2nd Jun 20064:48 pmRNSDirectors. dealings
1st Jun 20067:01 amRNSSellafield Agreement
31st May 200610:48 amRNSFirst Day of Dealings
4th Aug 20059:39 amRNSCompulsory Acquisition
29th Jul 200511:38 amRNSHolding(s) in Company
8th Jul 20054:36 pmRNSBoard Changes and Delisting
8th Jul 20057:00 amRNSOffer for Infast Group Update
6th Jul 20057:01 amRNSOffer for Infast Group Update
28th Jun 20055:27 pmRNSOffer for Infast Group Update
20th Jun 20057:01 amRNSOffer for Infast Group Update
31st May 20054:30 pmRNSRule 8.4- Infast Group PLC
31st May 20059:57 amRNSRule 8.3- Infast Group PLC
27th May 20055:12 pmRNSOffer Document Posted-Amend
27th May 20053:58 pmRNSOffer Document Posted
26th May 20057:02 amRNSRecom. Offer for Infast Group
10th May 200512:48 pmRNSEPT Disclosure
9th May 200510:32 amRNSEPT Disclosure
4th May 200511:06 amRNSEPT Disclosure
29th Apr 200510:31 amRNSResult of AGM
28th Apr 20058:45 amRNSAGM Statement
26th Apr 200511:42 amRNSEPT Disclosure
26th Apr 200511:16 amRNSRule 8.3- Infast Group PLC
25th Apr 200512:00 pmRNSEPT Disclosure
22nd Apr 200511:25 amRNSEMM Disclosure
21st Apr 20053:36 pmRNSDisposal
20th Apr 200510:27 amRNSEMM Disclosure
14th Apr 20059:40 amRNSRule 8 - Infast Group PLC
13th Apr 20053:00 pmRNSRule 2.10 Announcement
13th Apr 200512:20 pmRNSStatement re Possible Offer
12th Apr 200510:04 amRNSHolding(s) in Company
8th Apr 20052:19 pmRNSHolding(s) in Company
7th Apr 20055:12 pmRNSHolding(s) in Company
3rd Mar 20057:01 amRNSFinal Results
15th Feb 20052:32 pmRNSDisposal

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.